Skip to main content
S&P 5007,656.98+0.86%DOW52,573.29+0.98%NASDAQ26,333.03+0.96%BTC$77,267.00+0.58%ETH$2,510.86+2.27%GOLD$4,390.00-0.39%OIL$99.99-2.43%
Smart Investors Daily
AL

NASDAQ · ALBO

Albireo Pharma, Inc.

Healthcare · Biotechnology

$44.15

Up+$0.00 (+0.00%)

Updated Sep 13, 2026, 2:00 AM

SID Score

—

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
915.89M
P/E ratio
-5.61
Dividend yield
0.00%
52-week range
— – —
Volume
1.24M
Avg. volume
591.26K

Price performance

ALBO price history

1M range · 0 trading sessions · Daily adjusted prices

ALBO does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest ALBO news

The latest Smart Investors Daily articles mentioning ALBO.

Stock researchCompany · Overview

ALBO research

Overview

Company profile and research snapshot.

Company profile

Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$44.00
Implied upside
—
Analysts
—
ALBO recent ratings
DateFirmRatingTarget
Feb 15, 2023HC Wainwright & Co.Neutral—
Jan 11, 2023GuggenheimNeutral—
Jan 11, 2023JefferiesHold—
Jan 11, 2023Cowen & Co.Market Perform—
Jan 10, 2023HC Wainwright & Co.Neutral—
Open full forecast

News briefing

No generated briefing is available yet.

businesswire.com · Dec 4, 2025

Albireo Energy Names Mergers and Acquisitions Executive

EDISON, N.J.--(BUSINESS WIRE)--Albireo Energy, a leading independent building controls and energy services provider and a Huron Capital portfolio company, today announced the appointment of Brad Freeman as Senior Vice President of Mergers and Acquisitions (M&A). Freeman will drive Albireo Energy's M&A pipeline, identifying strong partner companies, directing disciplined due diligence with Huron Capital, and overseeing the negotiation, closing, and integration of new acquisitions. “The A.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By